Aldo Nascimento

Aldo N. serves as a Principal Scientist at Nanite since March 2024, previously holding similar positions at Intellia Therapeutics, Inc., where contributions included leading the development of methods for screening miRNA master regulators in glioblastoma and analyzing RNAseq data. Earlier experience includes time at bluebird bio as a Scientist I, and a Postdoctoral Researcher role at the University of Virginia School of Medicine, focusing on signaling pathways in Ras-driven cancers. Aldo's academic background features a PhD in Oncology and Cancer Biology from the University of Virginia and an A.B. in Human Evolutionary Biology from Harvard University. Additionally, consulting experience at BenchSci involved guiding the development of an antibody search tool, and earlier research roles included work on PTSD biomarkers and biothreat agent analysis at notable institutions.